Editorial Perspectives On Cold Chain

  1. Inside Interius' Global Regulatory Strategy 12/13/2024

    Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy.

  2. The Patchwork Of Outsourced ADC Manufacturing 7/29/2024

    Antibody-drug conjugate (ADC) manufacturing is complicated, to say the least, and it relies on a diversity of expertise. In a recent Bioprocess Online Live event, Chief Editor Matt Pillar talks with expert panelists about how this unique modality requires unique manufacturing considerations.

  3. Where's The Case For Generative AI In Biopharmaceutical Manufacturing? 6/12/2024

    The early use cases for AI in the biopharmaceutical industry—at least, the early public use cases—have largely come from R&D, and more specifically, target identification and molecular design. Where are the use cases in biologics manufacturing, supply chain management, QMS, and operations, and what’s holding us back?

  4. RNA Vaccines: Just Scratching The Surface 12/28/2023

    RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.

  5. Biomanufacturing Capacity Crunch Part 2: Building Optionality 10/12/2022

    In conference event programming, in the trade press, and in water cooler conversation we’re making too many generalizations—which in turn create misperceptions—about the so-called biopharmaceutical manufacturing “capacity” crunch.

  6. Biomanufacturing Capacity Crunch: It's The Supply Chain's Fault 10/7/2022

    What's behind the protracted biopharma manufacturing capacity crunch, when will it end, and what are manufacturers doing to keep supply on track? During Biotech Week in Boston ad BioProcess International, CDMOs and sponsors weighed in.

  7. Public Health Preparedness: Why Public Dollars Must Prime Private Investment 3/7/2022

    The private equity model isn’t equipped to fund biotechs interested in preventing—or addressing— the next pandemic. Three experts weigh in on how public/private partnerships should work to unlock emerging biotech innovation in a public health emergency.

  8. Regenerating The Vasculature With Bioengineered Human Tissue 2/23/2022

    With two phase 3 trials resuting in its bioengineered blood vessels being implanted in some 460 human patients, regenerative medicine pioneer Humacyte is finding its footing in the $150 billion vascular repair, reconstruction, and replacement market. Now it's preparing to reinvent treatment for Type 1 Diabetes.

  9. Why One Biopharma Simultaneously Built Two CAR T Manufacturing Facilities On Two Separate Continents During A Pandemic 2/11/2022

    Cellectis SVP of U.S. Manufacturing and Site Head Steve Doares joined the company as it kicked off simultaneous construction of manufacturing plants in Raleigh and Paris—and just as the pandemic began wreaking havoc on biopharmaceutical supply chains. He lived to tell us about it.

  10. Reengineering Biologics Manufacturing And Access With Spirulina 1/24/2022

    The “democratization” of biologics requires cost, time, and resource elimination from cell culture to administration and every step in between. Here’s how one innovative emerging biotech is leveraging one of the world’s oldest and most prolific organisms to that end.